INTRODUCTION: Current National Comprehensive Cancer Network guidelines recommend neoadjuvant therapy for borderline resectable pancreatic adenocarcinoma to increase the likelihood of achieving R0 resection. A consensus has not been reached on the degree of venous involvement that constitutes borderline resectability. This study compares the outcome of patients who underwent pancreaticoduodenectomy with or without vein resection without neoadjuvant therapy. METHODS: A multi-institutional database of patients who underwent pancreaticoduodenectomy was reviewed. Patients who required vein resection due to gross vein involvement by tumor were compared to those without evidence of vein involvement. RESULTS: Of 492 patients undergoing pancreaticoduodenectomy, 70 (14 %) had vein resection and 422 (86 %) did not. There was no difference in R0 resection (66 vs. 75 %, p = NS). On multivariate analysis, vein involvement was not predictive of disease-free or overall survival. CONCLUSION: This is the largest modern series examining patients with or without isolated vein involvement by pancreas cancer, none of whom received neoadjuvant therapy. Oncological outcome was not different between the two groups. These data suggest that up-front surgical resection is an appropriate option and call into question the inclusion of isolated vein involvement in the definition of "borderline resectable disease."
INTRODUCTION: Current National Comprehensive Cancer Network guidelines recommend neoadjuvant therapy for borderline resectable pancreatic adenocarcinoma to increase the likelihood of achieving R0 resection. A consensus has not been reached on the degree of venous involvement that constitutes borderline resectability. This study compares the outcome of patients who underwent pancreaticoduodenectomy with or without vein resection without neoadjuvant therapy. METHODS: A multi-institutional database of patients who underwent pancreaticoduodenectomy was reviewed. Patients who required vein resection due to gross vein involvement by tumor were compared to those without evidence of vein involvement. RESULTS: Of 492 patients undergoing pancreaticoduodenectomy, 70 (14 %) had vein resection and 422 (86 %) did not. There was no difference in R0 resection (66 vs. 75 %, p = NS). On multivariate analysis, vein involvement was not predictive of disease-free or overall survival. CONCLUSION: This is the largest modern series examining patients with or without isolated vein involvement by pancreas cancer, none of whom received neoadjuvant therapy. Oncological outcome was not different between the two groups. These data suggest that up-front surgical resection is an appropriate option and call into question the inclusion of isolated vein involvement in the definition of "borderline resectable disease."
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: William F Regine; Kathryn A Winter; Ross Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett Journal: Ann Surg Oncol Date: 2011-03-10 Impact factor: 5.344
Authors: Ross A Abrams; Andrew M Lowy; Eileen M O'Reilly; Robert A Wolff; Vincent J Picozzi; Peter W T Pisters Journal: Ann Surg Oncol Date: 2009-04-24 Impact factor: 5.344
Authors: Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans Journal: J Gastrointest Surg Date: 2004-12 Impact factor: 3.452
Authors: Thomas J Howard; Nicholas Villanustre; Seth A Moore; John DeWitt; Julia LeBlanc; Dean Maglinte; Lee McHenry Journal: J Gastrointest Surg Date: 2003-12 Impact factor: 3.267
Authors: Sara L Zettervall; Tammy Ju; Jeremy L Holzmacher; Bridget Huysman; Gregor Werba; Anton Sidawy; Paul Lin; Khashayar Vaziri Journal: J Gastrointest Surg Date: 2019-04-03 Impact factor: 3.452
Authors: George A Poultsides; Thuy B Tran; Eduardo Zambrano; Lucas Janson; David G Mohler; Matthew W Mell; Raffi S Avedian; Brendan C Visser; Jason T Lee; Kristen Ganjoo; E John Harris; Jeffrey A Norton Journal: Ann Surg Date: 2015-10 Impact factor: 12.969
Authors: Alexandra M Roch; Michael G House; Jessica Cioffi; Eugene P Ceppa; Nicholas J Zyromski; Attila Nakeeb; C Max Schmidt Journal: J Gastrointest Surg Date: 2016-01-14 Impact factor: 3.452
Authors: Jin Ho Lee; Chang Moo Kang; Seung Min Bang; Jin Young Choi; Jin Sil Seong; Ho Kyoung Hwang; Sung Hoon Choi; Woo Jung Lee Journal: Medicine (Baltimore) Date: 2015-08 Impact factor: 1.889